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Insight into Parkinson’s Disease and -Synuclein Degradation via the Lysosome: -
Synuclein Localization Changes in Vps28 
 
Alexandra Ayala* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Summary 
 
The neurodegeneration pathology in Parkinson’s 
disease patients predominantly targets dopaminergic 
neurons in the midbrain. These neurons accumulate 
aggregated alpha-synuclein, which may be linked to 
cell death. The misfolding and buildup of -synuclein 
is thought to trigger its accumulation and aggregation. 
An attractive hypothesis states that excess amounts 
of -synuclein are due to dysfunctional degradation of 
the protein. Until recently, the proteasome was 
considered the major site for degrading alpha-
synuclein, but recent studies suggest that the 
lysosome may also be involved. To test this latter 
hypothesis, we employed a budding yeast model for 
-synuclein aggregation and toxicity to genetically 
evaluate the role of the multivesicular body (MVB) 
pathway, which is a major route used by proteins to 
target the yeast vacuole for degradation.  ESCRT-1 is a 
major protein complex in the MVB pathway. We asked 
whether alpha-synuclein would accumulate and 
increase toxicity in yeast that lacked important 
ESRCT-1 components, in this case vps28 or mvb12. 
We demonstrate that the absence of vps28 altered 
wildtype, A53T, and E46K -synuclein localization. 
Specifically, -synuclein shifted from being localized 
primarily on the plasma membrane to being diffuse 
and aggregated within the cytoplasm. In contrast, the 
mvb12 strain retained plasma membrane -synuclein 
localization. Our preliminary data indicates that the 
MVB pathway is involved in -synuclein degradation, 
but not all proteins within ESRCT-1 participate. 
Complete analysis of the remaining ESCRT-I proteins 
and other ESCRT complexes is needed to fully 
understand the role of sorting proteins and MVBs in 
the -synuclein lysosome degradation pathway. 
 
Introduction 
 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder, second only to Alzheimer’s 
disease. PD affects over 1 million people in the U.S. 
(Greenamyre and Hastings, 2004).  Symptomatically, 
patients develop movement deficits such as muscular 
rigidity, tremors, altered posture, and bradykinesia 
(Giasson and Lee, 2003). These symptoms are caused by 
the characteristic death of dopaminergic neurons in the 
substantia nigra of the midbrain, which is linked to the 
formation of - synuclein aggregates in the dying neurons 
(Spillantini et al. 1998).  
-Synuclein is a 140 amino acid protein, which 
aggregates and is known to interact with phospholipids. 
Despite this knowledge, its precise function remains 
unknown. -synuclein colocalizes with synaptic vesicles 
and is thought to be involved in vesicular transport (Cabin 
et al. 2002). -Synuclein misfolding correlates with both  
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sporadic and familial Parkinson’s disease. Although other 
mutants are linked to PD, in all cases -synuclein 
aggregates. In sporadic PD, -synuclein misfolds for 
unknown reasons; in familial PD, ,mutations in -synuclein 
cause misfolding. There are three -synuclein mutations: 
A30P, A53T, and E46K, (Polymeropoulos et al., 1997; 
Kruger et al. 1997, Zarranz et al. 2004). In all PD, however, 
insoluble -synuclein aggregates are unable to be 
degraded. 
Death of specific dopaminergic neurons is 
linked to -synuclein misfolding, aggregation, and to 
impaired degradation and oxidative damage. If -synuclein 
aggregates have a toxic effect on cells, then maybe 
degrading them could reduce cell death. - Synuclein is a 
key player in PD; thus, it is thought that if - synuclein 
degradation is better understood, to the possible treatment 
development could be possible.  
Cytoplasmic proteins are degraded by the 
proteasome, and lipid-binding proteins are generally 
degraded in the lysosome.  For the past ten to fifteen 
years, pharmacological and genetic evidence shows that 
-synuclein is degraded via the ubiquitin-proteasome 
system (UPS), (Cummings et al., 1999; Walter et al., 
2001). Mutations in proteasome enzymes accelerate 
neuropathology in mice (Rideout, 2004), while inhibition of 
proteasomal function accelerates -synuclein aggregation 
and consequently increases cell death (McNaught et el. 
2002). Recently, however, pharmacological evidence 
demonstrates that when lysosomal function is impaired, -
synuclein accumulates, resulting in an increase in toxicity 
and cell death (Lee et al. 2004). Although promising, this 
evidence lacks genetic support suggesting that the 
lysosome is -synuclein’s degradation site.  
Membrane bound proteins reach the lysosome 
via the multivesicular body (MVB) pathway. 
Monoubiquitinated proteins are recruited by a late 
endosome, MVB, and are sorted into the MVB lumen. 
Once the proteins are sorted into MVB vesicles, the MVB 
fuses with the lysosome and releases the captured 
proteins for degradation (Katzmann et al. 2001; Klinodky 
and Kim 2000). Interestingly, - synuclein aggregates in 
PD patients are ubiquitinated, suggesting that misfolded, 
accumulated -synuclein is being tagged for degradation 
but not reaching the degradation site. Dysfunctional 
degradation and aggregate resistance to degradation are 
possible causes of -synuclein aggregation and improper 
degradation.  
 In the MVB/lysosome pathway, proteins are 
recruited by the endosome’s membrane. This multipart 
membrane consists of many proteins and three protein 
complexes required for transport, called endosomal sorting 
complexes (ESCRT): ESCRT-I, -II, and -III (Katzmann et 
al. 2001; Katzmann et al. 2003). ESCRT-I is made up of 
four proteins.  In our study, the role of two such proteins, 
vps28 and mvb12, are analyzed in order to further 
understand the route for lysosomal degradation (Katzmann 
et al. 2001; Katzmann et al. 2003). 
 Budding yeasts are very practical organisms to 
study the MVB/lysosome pathway in PD because their 
vacuole is analogous to the lysosome (Outerio and 
Lindquist, 2003; Klionsky and Kim 2000). Additionally, the 
complete knockout library for yeast is available, providing 
means to study the genetic role of proteins in the 
MVB/lysosome pathway. Our yeast model was used to  
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Figure 1. -Synuclein Toxicity Analysis in BY4741 Parent Strain, Vps28D and Mvb12D. Averaged absorbance readings at 0, 3, 6, 12, 18, 24, 36, and 48 hours were 
plotted against time to produce growth curves. pYES2, GFP, A30P, A53T, and E46K cells were analyzed for BY4741, vps28D, and mvb12D. a) At 18, 24, and 36 hours, post 
induction, growth was reduced in E4K in 4741. Toxicity was not observed in other plasmids in 4741.  b) Growth was reduced in E46K in Vps28D at 18, 24, and 36 hours post 
induction. Reduced growth was not observed in the other plasmids. c) In mvb12D, no toxicity was observed in E46K. Growth was not reduced in all other plasmids, cells were 
healthy.   
 
provide evidence for -synuclein degradation via the 
lysosome, using the MVB/endosomal pathway to gain 
access to the lysosome. Vps28 and mvb12 knockout 
strains expressing -synuclein were used to evaluate any 
affect on -synuclein localization, expression, and toxicity 
to the cell, an indication of perturbed degradation. Protein 
deletions showed no increase in toxicity or expression; 
however, vps28 did increase -synuclein cytoplasmic 
accumulation. 
 
Results 
 
-Synuclein has No Effect on Vps28 and Mvb12 Cell 
Growth  
To test if -synuclein is toxic to MVB knockout yeast, 
optical density growth analysis was performed at 600 nm. 
Absorbance readings were taken at 0, 3, 6, 12, 18, 24, 36, 
and 48 hours post-induction. Averaged absorbance 
readings were plotted against time to produce a growth 
curve. Growth patterns were observed in vps28 and 
mvb12 expressing WT, A30P, A53T, and E46K, and 
were compared to, parent strain, BY4741 growth curves 
done by Michael White. In both vps28 and mvb12 all 
constructs, with the exception of E46K, grew similarly to 
cells in the parent strain (Fig. 1). Vps28 cells expressing 
E46K showed exhibited decreased growth 18 and 24 
hours. This growth pattern was similar to that observed in 
the parent strain (Fig. 1A and 1B). At 18 hours, E46K had 
less absorbance than all other cell types. Finally, a growth 
curve analysis was done with E46K cells in BY4741 and 
vps28 strains (data not shown). Absorbance readings 
were similar at all times, and no additional toxicity was 
observed. In mvb12 E46K toxicity was not observed; The 
E46K cells grew equal to cells in all other vectors (Fig. 1C). 
 
-Synuclein Localization Changes in Vps28 
-Synuclein-GFP localization was evaluated in GFP 
fluorescence images acquired at 24 and 48 hours post-
induction. Empty vector and GFP-pYES2 were used as 
controls in our GFP fluorescence microscopy. Parent strain 
(BY4741) microscopy pictures are courtesy of Michael 
Zorniak. Parent strain images were used as a template to 
which vps28 images were compared. In 4741, WT and 
A53T -synuclein was membrane bound, and A30P was 
cytoplasmically diffuse after 24 and 48 hours (Fig. 2A and 
2D), consistent with previous studies (Sharma, 2007). 
However, at 24 hours, E46K -synuclein was both 
membrane localized and cytoplasmically diffuse. By 48 
hours E46K was predominantly cytoplasmically diffuse. 
Similar to 4741, both GFP and A30P in vps28 are 
cytoplasmically diffuse at 24 and 48 hours. However, WT 
and A53T, in vps28 become predominantly diffuse (Fig. 
2B and 2E). E46K was both membrane localized and 
diffuse at 24 and 48 hours (Fig. 2B and 2E). 
 
No Change in -Synuclein Localization in Mvb12 
GFP fluorescence microscopy was used to analyze -
synuclein localization in mvb12 at 24 and 48 hours post-
induction. Compared to BY4741, mvb12 showed no 
change in -synuclein localization. A30P remained diffuse, 
while WT, A53T, and E46K -synuclein were membrane 
localized. (Fig. 2C and 2F). 
 
No Change in -Synuclein Expression in BY4741 Parent 
Strain and Vps28 
-Synuclein expression was evaluated in BY4741 and 
vps28 at 48 hours post-induction -Synuclein-V5 
expression was measured using a V5 antibody. -
Synuclein expression was equal in all constructs in 4741 
and Vps28. A PGK antibody was used as a loading 
control confirming equal loading amounts. pYES2, empty 
vector, was used as a negative control. In both the parent 
strain and vps28 wildtype and mutant -synuclein were 
equally expressed. 
 
Discussion 
 
Although the formation of -synuclein aggregates is linked 
to impaired degradation, we are still unclear on whether 
aggregates resist degradation or if dysfunctional 
degradation exists. In order to answer these questions, we 
first need to better understand -synuclein degradation. 
For the past four years, an increasing number of studies  
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Figure 2. Change in a-Synuclein Localization in Vps28D. WT, A30P, A53T, and E46K a-synuclein with C-terminus GFP tags localization was visualized in BY4741, 
vps28D, and mvb12D. Images were taken at 24 and 48 hours post-induction. Approximately 750 cells were counted for each construct and percent phenotypes were plotted 
against time.  A and D) WT and A53T a-synuclein in BY4741 was membrane localized (halo) at 24 and 48 hours. E46K was memebrane localized at 24 hours and was 
cytoplasmically diffuse (diffuse) at 48 hours. A30P was cytoplasmically diffuse at both time points. B and E) In vps28D WT, A30P and A53T a-synuclein was predominantly 
cytoplasmically diffuse.  C and F) In mvb12D a-synuclein localization was the same as in 4741.  
 
have provided evidence suggesting that -synuclein is 
degraded by the lysosome (Lee et al., 2004; Cuervo et al., 
2004). However, genetic evidence is needed to further 
support this hypothesis. Our study provides some insight 
into -synuclein degradation via the MVB/lysosome 
pathway.  
 
Compromising the MVB/lysosome Pathway Alters -
Synuclein’s Membrane Localization 
Our preliminary data implicates the MVB/endosome 
pathway in the regulation of -synuclein localization, 
suggesting that the lysosome is a site for -synuclein 
degradation. In our study, an ESCTR-1 sorting protein 
known as vps28 was knocked out. Subsequently, -
synuclein shifted from being primarily localizing on the 
membrane to being largely diffuse throughout the 
cytoplasm. This suggests that vps28 has a role in -
synuclein’s phospholipid interaction. Now in the cytoplasm, 
-Synuclein is susceptible to the formation of intracellular 
inclusions and will no longer be degraded by the lysosome.  
However, the vps28 knockout had no major 
effects on toxicity patterns or on -synuclein expression. 
E46K cells were the only cells that showed toxicity in 
vps28 E46K toxic growth pattern in vps28 was similar to 
the E46K toxic effect in BY4741 parent strain. When 
comparing parent strain and vps28 E46K growing curves, 
both were very similar, indicating that the toxic effect 
observed in the vps28 strain was simply due to the E46K 
mutation and not to the knocked out vps28 protein. Overall, 
with the exception of E46K in mvb12, cells had no 
change in growth patterns, suggesting that cells lacking 
these MVB proteins remain as healthy as parent strain 
cells. 
 We also know that not all proteins in this 
degradation pathway have an effect on -synuclein. When 
mvb12, another ESCRT I protein, was knocked out, there  
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Figure 3. a-Synuclein Expression Analysis in BY4741 Parent Strain and 
Vps28D.Western blots analysis was used to evaluate a-synuclein expression in 
BY4741 and vps28D 24 hours post induction. PGK antibody was used as a 
loading control. GFP and pYES2 were also controls. A) WT, A30P, A53T, and 
E46K -synuclein have equal expression in 4741; B) WT, A30P, A53T, and 
E46K a-synuclein also show equal expression in vps28D.  
 
was no change in -synuclein localization, toxicity, or 
expression. While ESCRT-1 is involved, not all of its 
protein components may be critical for the regulation of -
synuclein degradation. This also suggests that other 
proteins or components in this pathway may be essential 
for the degradation pathway, but are not specific to the 
regulation of -synuclein degradation, and that only some 
are necessary. 
 
Absence of -Synuclein Toxicity 
The first question to answer relates to the seeming 
paradox evident in cells with compromised degradation 
pathways: why do such cells grow healthily and show no 
signs of toxicity? One reason for this is the fact that 
membrane localization is needed for toxicity. In vps28 
cells, which show different membrane localization, -
synuclein is no longer found on the membrane. Instead, it 
is often located in the cytoplasm. However, we also realize 
that cells with membrane localization, including the parent 
and mvb12 strain, are also healthy. This is because in 
order for -synuclein to have a toxic effect, membrane 
localization is necessary. A second reason is that, because 
the lysosome is being compromised, the proteasome may 
be activated in order to compensate for lysosomal loss. 
Since -synuclein is found in the cytoplasm of vps28 
cells, the proteasome would be the likely degradation site, 
which is also known to play a role in -synuclein 
degradation (Cummings et al., 1999; Walter et al., 2001; 
Ma et al. 2002). Finally, protective factors or responses 
may be induced when there is lysosomal dysfunction in the 
cell.  
Our data, showing that a compromised 
MVB/lysosome degradation pathway alters -synuclein 
localization, provides preliminary evidence that -synuclein 
is degraded by the lysosome and uses the MVB pathway 
to get to the lysosome. Although we observed no toxicity or 
change in -synuclein expression, we did observe a 
change in -synuclein localization with the elimination of 
one MVB protein. In this study we have shown that 
although not all proteins in the MVB/endosome pathway 
play a role in -synuclein localization, ESCRT-1’s vps28 
protein does indeed play a role, implicating the pathway for 
-synuclein degradation.  
Future research will complete analysis on 
remaining ESCRT I proteins and other ESCRT complexes 
for their ability to regulate -synuclein misfolding, 
localization, and toxicity. In order to further understand the 
role of the MVB/lysosome pathway in -synuclein 
degradation, we need to first understand which proteins 
are most important for degradation. Also, we would like to 
test synergistic effects by combining MVB dysfunction with 
either pharmacologically compromised proteasomes or 
induced oxidative stress. Since we suspect that the 
proteasome is compensating for lysosomal loss, we would 
expect to see toxicity in cells that have compromised 
proteasomes and lysosomes. Anther option is to run a 
western blot for proteasomal enzymes in order to see if 
there is increased expression of these proteins in vps28, 
which we would expect. And finally, we must evaluate 
induction of apoptosis, autophagy, and vacuolar integrity 
as cellular responses to reduced MVB regulation of -
synuclein degradation. 
 
Methods 
 
-Synuclein Constructs  
Human wild-type and A53T mutant -synuclein cDNAs were a gift 
from Christopher Ross (Johns Hopkins University).  A30P and 
E46K were created from wild-type and -synuclein using site-
directed mutagenesis (Invitrogen) and mutations were confirmed by 
sequencing (University of Chicago).  Wild-type and mutant -
synuclein cDNAs were subcloned into the pYES2.1/V5-His-TOPO 
yeast expression vector (Invitrogen).  All -synuclein forms were 
tagged with GFP using a two-step cloning strategy, with GFP either 
tagged at the N- or C-terminus. -Synuclein cDNAs were first 
subcloned into mammalian expression vectors, pcDNA3.1/C-
terminal GFP (Invitrogen) in order to be fused with GFP at the C-
terminus. GFP tagged -synuclein genes were then PCR-amplified 
and subcloned into pYES2.1/V5-His-TOPO yeast expression vector 
(Invitrogen). Chemically competent E. coli cells were transformed 
with the -synuclein, -synuclein-GFP, and GFP- -synuclein 
pYES2.1/V5-His-TOPO vectors. The parent pYES2.1 vector 
(Invitrogen) and GFP in pYES2.1/V5-His-TOPO vector were used 
as controls. 
 
Yeast Strains 
BY4741 (mat a), vps28 (BY4741 parent), and mvb12 (BY4741 
parent) were purchased from Open Biosystems. 
 
Yeast Expression 
-Synuclein expression plasmid vectors were transformed into 
budding yeast strains as described in Burke et al. (2000). For 
selection, yeast cells were grown on synthetic-complete media 
lacking uracil (SC-Ura).  Presence of -synuclein constructs was 
confirmed by PCR. The pYES2.1 vector, containing a galactose 
inducible promoter (GAL1), allowed for regulated -synuclein 
expression.  Yeast cells were first grown overnight in SC-Ura 
glucose (2%) or SC-Ura raffinose (2%) media at 30°C and 200 rpm.  
Cells were washed with water and diluted to log-phase (5 x 10^6 
cells/ml) in SC-URA galactose (2%) media to induce expression 
and grown to the time points desired for various measurements.  
        
Western Analysis 
Yeast cells (2.5x10
 7
 cells/mL) were washed in 50 mM Tris (pH 7.5), 
10 mM NaN3 and solubilized in Electrophoresis Sample Buffer 
(ESB; Burke, 2000) containing 2% sodium dodecyl sulfate (SDS), 
80 mM Tris (Ph 6.8), 10% glycerol, 1.5% dithiothreitol, 1 mg/ml 
bromophenol blue, and a cocktail of protease inhibitors and 
solubilizing agents (1% Triton-X 100, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM benzamidine, 1 mM sodium orthovanadate, 0.7 
mg/ml pepstatin A, 0.5 mg/ml leupeptin, 10 mg/ml E64, 2mg/ml 
aprotinin, and 2 mg/ml chymostatin).   Samples were run on pre-
cast 10-20% Tris-Glycine gels (Invitrogen) using SDS containing 
running buffer. SeeBlue (Invitrogen) was used as the molecular 
standard. Gels were transferred to PVDF membranes and Western 
blot was performed with different monoclonal antibodies using 
standard protocols and detected for alkaline phosphatase activity: 
anti-V5 (Invitrogen) and anti-phosphoglycerokinase (PGK; 
Molecular Probes) for most expression experiments, as a measure 
of loading control in duplicate blots. 
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Growth Curve Analysis 
Cells were grown in 10 ml SC-URA glucose overnight at 30°C, 200 
rpm. Cells were harvested at 1500 x g for 5 min at 4°C, and were 
washed twice in 5 ml H20. Cells were re-suspended in 5 mL H20 
and were counted. Flasks with 25 ml SC-URA galactose were 
inoculated to 2.0x10
6
 cells/ml density. At 0, 3, 6, 12, 18, 24, 36 and 
48 hours, and in duplicate measurements, 1 ml of cell culture was 
removed and placed in a cuvet to measure absorbance using a 
Hitachi U-2000 Spectrophotometer. Averaged absorbance readings 
were plotted against time to produce a growth curve.  
 
GFP Microscopy 
Cells were grown overnight in 10 ml SC-URA glucose at 30°C at 
200 rpm. Protein expression was induced with SC-URA galactose 
media. After a time specific induction, cells were harvested at 
1500xg at 4°C for 5 minutes and were washed twice with 5 ml H20. 
Cells were re-suspended in 100-1000ml SC-URA glucose, and 10 
ml cell suspension was pipeted onto a slide. Cells were visualized 
under a Nikon TE2000-U fluorescent microscope and images were 
acquired and analyzed using Metamorph 4.0 imaging software. 
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